Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing
holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Abstract Background DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer
patients represent promising biomarkers for minimally invasive tumor detection. The high …

Background and aims Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations
is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter …

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative
review - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Background Detection of circulating tumour DNA (ctDNA) in biological fluids is a minimally
invasive alternative to tissue biopsy for therapy monitoring. Cytokines are released in the …

Background Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC)
inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma …

Purpose: Analysis of methylation markers in liquid biopsies is a promising technique for the
follow-up of patients with metastatic colorectal cancer (mCRC), because they can be used in …

Background Liquid rebiopsies can detect resistance mutations to guide therapy of anaplastic
lymphoma kinase-rearranged (ALK+) non-small-cell lung cancer (NSCLC) failing tyrosine …

Simple Summary Lung cancer is a devastating disease, with non-small cell lung cancer
(NSCLC) being the most common subtype. With the development of novel targeted …